Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

A better-than-expected earnings report lifted shares of the telehealth company.

Why Teladoc Stock Jumped 17% in October

Teladoc (TDOC) projects total visits in the band of 18.4-18.6 million for 2022.

Teladoc (TDOC) Up 1.6% Since Q3 Earnings Beat on Higher Visits

Vertex Pharmaceuticals

Don't overlook these major healthcare names on your next stock-buying spree.

Got $1,000? 2 Smart Stocks to Consider Buying Right Now

FedEx

One investor's down market is another's golden opportunity.

Have $2,000? 2 Beaten-Down Stocks to Consider Buying on the Dip

A lackluster year for Teladoc Health may represent a good opportunity for long-term investors.

Is This Beaten-Down Growth Stock Undervalued?

Microsoft

AT&T

There are options here for you whether you're focused on dividends, growth, or long-term safety.

Where to Invest $500 in November

The company's recent earnings report featured many positives.

3 Reasons I'm Still Bullish On Teladoc

Johnson & Johnson

A volatile market environment presents opportunities for the forward-thinking investor.

2 Compelling Stocks to Buy in a Bear Market

Medtronic

Ontario Paramedic Service is the fifth County to choose Cloud DX Connected Health™ to improve positive patient outcomes as part of its Community Paramedicine Remote Monitoring program News in Summary As hospital-at-home and community remote monitoring programs increase in scale, Cloud DX expects to deploy over 1,000 Connected Health kits for this use case by early 2023. Paramedicine deployments are funded through the $82 million Community Paramedicine Long Term Care Program.

Cloud DX Announces 6th Ontario Paramedicine Group Contract

The consensus price target hints at a 53.6% upside potential for Teladoc (TDOC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Teladoc (TDOC) Could Rally 54%: Here's is How to Trade

Investors want to know if this stock's recent gains are the beginning of a long bull run.

Is Teladoc Health a Good Stock to Buy Right Now?

The healthcare technology company made an ill-timed acquisition that was causing the losses.

Investors Thrilled After Absence of "Write-down" During Teladoc's Q3

Teledoc ( TDOC , Financial) has had a tough time recently, facing mounting pressures from competitors. But after a couple of difficult quarters, Teledoc is back in business, beating consensus estimates on both the top and bottom lines in its third-quarter earnings results.

Teledoc Exits Earnings With a Clean Bill of Health

Intuitive Surgical

These stocks are both trading down by double-digits over the past year, but there's much more for investors to take into account.

Got $1,500? These 2 Stocks Could Be Bargain Buys for 2022 and Beyond

Amazon

Moderna

The future looks bright for these companies.

3 Beaten-Down Growth Stocks That Could Crush the Market

The painful writedown of Livongo Health has been done, and Teladoc continues to grow.

Still Down 90%, Here's Why Teladoc Health Stock Is a Buy After Earnings

Teladoc may have reached a turning point.

Should You Really Buy Teladoc Right Now?

Strong results helped lift the telehealth company.

Why Teladoc Health Stock Charged Sharply Higher This Week

Sales of $611 million top analysts' expectations.

Teladoc Stock Is Rising on Narrower-Than-Forecast Loss

Teladoc Health   (NYSE:TDOC) is up 6.2% to trade at $28.60 at last check, after posting slimmer-than-expected third-quarter losses of 47 cents per share, as well as a revenue win of $611.40 million, thanks to strong subscription numbers.

Teladoc Health Stock Brushes Off Post-Earnings Bear Notes

Teladoc Health (NYSE: TDOC ) stock rose more than 10% overnight after the company reported strong growth and narrower losses with its third-quarter earnings. Now, TDOC stock is up 5% so far today.

Why Is Teladoc (TDOC) Stock Up 5% Today?

Align Technology

Teladoc Health is "hitting its stride," one analyst said Thursday as TDOC stock surged on its third-quarter beat. The post Why Pandemic Darlings Teladoc, Align Diverged On Their Third-Quarter Reports appeared first on Investor's Business Daily.

Why Pandemic Darlings Teladoc, Align Diverged On Their Third-Quarter Reports

The bottom line is the bottom line with Teladoc's Q3 results.

Here's the Surprise That's Driving Teladoc Health Stock Higher

Although this quarter was better than the last one, we're not out of the woods yet.

Is Teladoc Stock Finally a Buy After Its Recent Earnings Report?

Teladoc Health, Inc. (NYSE:TDOC ) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Patrick Feeley - VP, IR Jason Gorevic - CEO & Director Mala Murthy - CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co Richard Close - Canaccord Genuity Jailendra Singh - Truist Securities Daniel Grosslight - Citigroup Cindy Motz - Goldman Sachs Jessica Tassan - Piper Sandler & Co. Charles Rhyee - Cowen and Company Sameer Patel - Evercore Sean Dodge - RBC Capital Markets Ryan Daniels - William Blair & Company Stephanie Davis - SVB Securities George Hill - Deutsche Bank Operator Hello and welcome to the Teladoc Health Third Quarter 2022 Earnings Conference Call. My name is Alex, and I'll be coordinating the call today.

News for Teladoc Stock (TDOC)